All News
Day 3 EULAR Report
Day 3 was an interesting mix of posters, oral presentations, and review sessions on many practical subjects like osteoarthritis, large vessel vasculitis, systemic sclerosis, and pregnancy. Here are a few of my recommended abstracts from Friday at EULAR 2026.
Read Article
5 years since Patient ID001: Progress on CAR-T Therapy in RMD
Five years on, are we closer to licensing of the first CAR-T therapy in rheumatic and musculoskeletal diseases (RMD)?
Read Article
How to treat SLE in 2026 and beyond!
There are so many SLE trials, and over the last year, many new ideas have been suggested.
Read Article
Updates in SLE and APS
2026 EULAR Press Release
Systemic lupus erythematosus (SLE) and antiphospholipid syndrome (APS) often overlap. While there have been some therapeutic advances, significant needs remain around diagnosis and monitoring, with a gap around definitions and biomarkers for refractory disease or specific subsets.
Read Article
#EULAR2026 POS1355 A cohort study in Japan identified 5-score predictors of GC-free remission in #lupusnephritis: HCQ, pulsed IV GC, Chronicity index=0, =>75% UPCR reduction by 6mo,& 12 mths CRR. Data cutoff 2024. Interested to see impact of current Combo tx from outset @RheumNow https://t.co/qmpgyEyOOV
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
#EULAR2026 POS0172 #Lupus arthritis is the most common domain in RCTs but SLEDAI-MSK or BILAG-MSK isn’t satisfactory. Look out for the role out of LAMDA once externally validated using independent trial datasets. 4 candidates: SJC28, ESR, VAS Phy MSK, & VAS Pa Pain @RheumNow https://t.co/QJ51ETLSSN
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
A biomarker for CV disease in RA?
Anti-CXCR3 antibodies asso w/ atherosclerosis
Confirmed in a validation cohort
Adding Ab profile to the mSCORE increases
AUC from 0.6 to 0.9
Sens from 30 to 69%
How does it compare with other ways of detecting atherosclerosis?
#POS0899 https://t.co/O7bsLrVyzo
Links:
Aurelie Najm AurelieRheumo ( View Tweet)
Can we have an effective, comprehensive score for
#SLE #arthritis?
#SLEDAI has a problem
SJC>2 scores dames as ex #SJC=12
Meet
#LAMBDA
An attempt to improve a true positive #MSK OUTCOME in #lupus
Needs validation esp in pts over time
#EULAR2026 @RheumNow #POS1072
@eular_org https://t.co/fr0xuVqFnM
Janet Pope Janetbirdope ( View Tweet)
#EULAR2026 POS0306 Can we predict #lupus nephritis pts who would achieve CR at 12 mths? Monocentric study used M.Learning: developed & internally validated 5 Clinical Score (LUPRED) with AUC 0.75 training set, 0.78 validation. Simple to use but needs external validation @RheumNow https://t.co/1VRE1yBCac
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
#EULAR2026 POS0713 Is there a hope for BTK-inhibition in #SLE despite several previous failures? A Phase IIb RCT in China: primary endpoint (SRI-4) was met in Orelabrutinib vs PBO in dose-dependent manner. No new safety signal. Phase 3 RCT is underway @RheumNow https://t.co/4cJ8ezppTS
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
#proof of #concept in #Sjogren’s #dis
#lanalumab Treatment reduced in #SjD
✅reduced B cells in #salivary #glands
—nearly complete depletion in serum
✅reduced B cell activation
✅improved #inflammation of
#parotid & #submandibular glands
@RheumNow #EULAR2026
#OP0163
#POS0284
Janet Pope Janetbirdope ( View Tweet)
Interim results from ASTER, a study on real world effectiveness of ANI in SLE: Pts receiving ANI had improvements in total SLEDAI-2K scores after 1 yr ffup period
MCT, MSK & hema had the highest decrease in SLEDAI-2K scores from pre-tx to 1yr ffup
OP342 @RheumNow #EULAR2026 https://t.co/DArOwQtxM6
Links:
sheila RHEUMarampa ( View Tweet)
#EULAR2026 POS0156 “TWO’S company, THREE’S a crowd” Tri-specific CD19/CD3/CD28 (i.e. CD28 co-stimulates Tcell activation) TriTE via IV showed early efficacy & safety in 11 #SLE patients up to 48WKS. Longer FU needed to see if repeat dosing needed @RheumNow https://t.co/FpXzJIYwZF
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
#OP0342 Interim real-world ASTER data showed anifrolumab improved overall SLEDAI-2K scores & reduced disease activity across multiple organ systems over 12 months, particularly mucocutaneous & MSK domains. Nearly 30% achieved SLEDAI-2K=0 at 1 year. #EULAR2026 @RheumNow https://t.co/IJlDnHSTh2
Mrinalini Dey DrMiniDey ( View Tweet)
#OP0336 Exploratory analyses from REGENCY👑 OBI +standard tx induced ⬆️ histological remission & markedly greater kidney tissue B-cell depletion vs PBO in lupus nephritis. Many patients without clinical CRR still achieved histologic remission. #EULAR2026 @RheumNow #EULARBest https://t.co/DoOlRO9QsC
Mrinalini Dey DrMiniDey ( View Tweet)
#OP0340 Long-term DARALUP data suggest CD38-targeting with daratumumab may be promising in refractory SLE, with rapid serologic and clinical improvements sustained to 84 weeks in many patients. Flares occurred in 6/10 patients but responded to belimumab. #EULAR2026 @RheumNow
Mrinalini Dey DrMiniDey ( View Tweet)
Post marketing safety signals of anifrolumab from US FDA adverse event reporting system - herpes zoster significantly associated.
Others include infusion reactions and intermittent hypersensitivity @RheumNow ##EULAR2026 #POS1067
Bella Mehta bella_mehta ( View Tweet)
#EULAR2026 POS0683 Additional analysis of ALLEGORY RCT: in addition to meeting primary endpoint (SRI-4) and 5 key secondary endpoints, Obinutuzumab led to greater DORIS remission and LLDAS vs PBO in nonrenal #SLE. Under FDA review for license extension to non-renal @RheumNow https://t.co/HhZNX3w8v5
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
#EULAR2026 OP0341 Phase I Obe-Cel Autologous CD19 CAR-T (advantage: 4-1BB-ζ, fast off-rate binding domain to reduce immunotoxicity) showed efficacy and acceptable safety with either 50M or 100M dose in N=13 patients with refractory #SLE. Need longterm data & comparators @RheumNow https://t.co/qxidRi0jit
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
OMRF study: Anti-Ro neg Sjögren’s patients share similar molecular profiling as anti-Ro positive pts: innate immune signaling, immune cell activation, inflammation, autophagy, apoptosis, and metabolic dysregulation pathways #EULAR2026 @RheumNow https://t.co/zJm6EbpyIB
TheDaoIndex KDAO2011 ( View Tweet)
